For Physicians

Text

Placeholder text (you can add a block title above)

You are here

Home › OGX-427-BL01

OGX-427-BL01

An investigator sponsored Phase 1 trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of OGX-427 when administered directly into the bladder of patients with superficial bladder cancer.

Study Design: 
An investigator sponsored Phase 1 trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of OGX-427 when administered directly into the bladder of patients with superficial bladder cancer.
Arm A: 
c